Renal Cell Carcinoma and Targeted Therapy

Benjamin A. Gartrell, Alexander C. Small, William K. Oh, Matthew D. Galsky

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Renal cell carcinoma (RCC) is generally resistant to cytotoxic chemotherapy. Clear-cell RCC (ccRCC) is the most common histology accounting for 80-90% of tumors. This chapter explores the molecular pathogenesis of RCC, and the targeted therapies that have recently been developed. The genetics of VHL disease follow the "two hit" model of tumor suppressor gene function first proposed by Knudson. Next-generation sequencing has been used to evaluate tumor heterogeneity in RCC. The chapter talks about the important signaling pathways in RCC, including the mammalian target of the rapamycin (mTOR) pathway. Renal carcinoma is a vascular tumor and VEGF has been detected in high levels in the serum of patients with RCC. With elucidation of key molecular mechanisms of disease, vascular endothelial growth factor (VEGF)/vascular endothelial growth factor receptors (VEGFR) and target of the mTOR emerged as promising targets which have now been validated in large clinical trials.

Original languageEnglish (US)
Title of host publicationTargeted Therapy in Translational Cancer Research
PublisherWiley Blackwell
Pages287-295
Number of pages9
ISBN (Electronic)9781118468678
ISBN (Print)9781118468579
DOIs
StatePublished - Oct 30 2015

Fingerprint

Renal Cell Carcinoma
Sirolimus
Vascular Endothelial Growth Factor A
Therapeutics
Neoplasms
Inborn Genetic Diseases
Vascular Endothelial Growth Factor Receptor
Tumor Suppressor Genes
Blood Vessels
Histology
Clinical Trials
Carcinoma
Kidney
Drug Therapy
Serum

Keywords

  • Mammalian target
  • Rapamycin pathway
  • Renal cell carcinoma
  • Targeted therapy
  • Tumor suppressor gene function
  • Vascular endothelial growth factor

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Gartrell, B. A., Small, A. C., Oh, W. K., & Galsky, M. D. (2015). Renal Cell Carcinoma and Targeted Therapy. In Targeted Therapy in Translational Cancer Research (pp. 287-295). Wiley Blackwell. https://doi.org/10.1002/9781118468678.ch29

Renal Cell Carcinoma and Targeted Therapy. / Gartrell, Benjamin A.; Small, Alexander C.; Oh, William K.; Galsky, Matthew D.

Targeted Therapy in Translational Cancer Research. Wiley Blackwell, 2015. p. 287-295.

Research output: Chapter in Book/Report/Conference proceedingChapter

Gartrell, BA, Small, AC, Oh, WK & Galsky, MD 2015, Renal Cell Carcinoma and Targeted Therapy. in Targeted Therapy in Translational Cancer Research. Wiley Blackwell, pp. 287-295. https://doi.org/10.1002/9781118468678.ch29
Gartrell BA, Small AC, Oh WK, Galsky MD. Renal Cell Carcinoma and Targeted Therapy. In Targeted Therapy in Translational Cancer Research. Wiley Blackwell. 2015. p. 287-295 https://doi.org/10.1002/9781118468678.ch29
Gartrell, Benjamin A. ; Small, Alexander C. ; Oh, William K. ; Galsky, Matthew D. / Renal Cell Carcinoma and Targeted Therapy. Targeted Therapy in Translational Cancer Research. Wiley Blackwell, 2015. pp. 287-295
@inbook{4bf5ad5f716f4186af42bb86fcd0bff8,
title = "Renal Cell Carcinoma and Targeted Therapy",
abstract = "Renal cell carcinoma (RCC) is generally resistant to cytotoxic chemotherapy. Clear-cell RCC (ccRCC) is the most common histology accounting for 80-90{\%} of tumors. This chapter explores the molecular pathogenesis of RCC, and the targeted therapies that have recently been developed. The genetics of VHL disease follow the {"}two hit{"} model of tumor suppressor gene function first proposed by Knudson. Next-generation sequencing has been used to evaluate tumor heterogeneity in RCC. The chapter talks about the important signaling pathways in RCC, including the mammalian target of the rapamycin (mTOR) pathway. Renal carcinoma is a vascular tumor and VEGF has been detected in high levels in the serum of patients with RCC. With elucidation of key molecular mechanisms of disease, vascular endothelial growth factor (VEGF)/vascular endothelial growth factor receptors (VEGFR) and target of the mTOR emerged as promising targets which have now been validated in large clinical trials.",
keywords = "Mammalian target, Rapamycin pathway, Renal cell carcinoma, Targeted therapy, Tumor suppressor gene function, Vascular endothelial growth factor",
author = "Gartrell, {Benjamin A.} and Small, {Alexander C.} and Oh, {William K.} and Galsky, {Matthew D.}",
year = "2015",
month = "10",
day = "30",
doi = "10.1002/9781118468678.ch29",
language = "English (US)",
isbn = "9781118468579",
pages = "287--295",
booktitle = "Targeted Therapy in Translational Cancer Research",
publisher = "Wiley Blackwell",

}

TY - CHAP

T1 - Renal Cell Carcinoma and Targeted Therapy

AU - Gartrell, Benjamin A.

AU - Small, Alexander C.

AU - Oh, William K.

AU - Galsky, Matthew D.

PY - 2015/10/30

Y1 - 2015/10/30

N2 - Renal cell carcinoma (RCC) is generally resistant to cytotoxic chemotherapy. Clear-cell RCC (ccRCC) is the most common histology accounting for 80-90% of tumors. This chapter explores the molecular pathogenesis of RCC, and the targeted therapies that have recently been developed. The genetics of VHL disease follow the "two hit" model of tumor suppressor gene function first proposed by Knudson. Next-generation sequencing has been used to evaluate tumor heterogeneity in RCC. The chapter talks about the important signaling pathways in RCC, including the mammalian target of the rapamycin (mTOR) pathway. Renal carcinoma is a vascular tumor and VEGF has been detected in high levels in the serum of patients with RCC. With elucidation of key molecular mechanisms of disease, vascular endothelial growth factor (VEGF)/vascular endothelial growth factor receptors (VEGFR) and target of the mTOR emerged as promising targets which have now been validated in large clinical trials.

AB - Renal cell carcinoma (RCC) is generally resistant to cytotoxic chemotherapy. Clear-cell RCC (ccRCC) is the most common histology accounting for 80-90% of tumors. This chapter explores the molecular pathogenesis of RCC, and the targeted therapies that have recently been developed. The genetics of VHL disease follow the "two hit" model of tumor suppressor gene function first proposed by Knudson. Next-generation sequencing has been used to evaluate tumor heterogeneity in RCC. The chapter talks about the important signaling pathways in RCC, including the mammalian target of the rapamycin (mTOR) pathway. Renal carcinoma is a vascular tumor and VEGF has been detected in high levels in the serum of patients with RCC. With elucidation of key molecular mechanisms of disease, vascular endothelial growth factor (VEGF)/vascular endothelial growth factor receptors (VEGFR) and target of the mTOR emerged as promising targets which have now been validated in large clinical trials.

KW - Mammalian target

KW - Rapamycin pathway

KW - Renal cell carcinoma

KW - Targeted therapy

KW - Tumor suppressor gene function

KW - Vascular endothelial growth factor

UR - http://www.scopus.com/inward/record.url?scp=85015832128&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85015832128&partnerID=8YFLogxK

U2 - 10.1002/9781118468678.ch29

DO - 10.1002/9781118468678.ch29

M3 - Chapter

SN - 9781118468579

SP - 287

EP - 295

BT - Targeted Therapy in Translational Cancer Research

PB - Wiley Blackwell

ER -